MX378368B - Receptores de antigeno y usos de los mismos. - Google Patents
Receptores de antigeno y usos de los mismos.Info
- Publication number
- MX378368B MX378368B MX2018004121A MX2018004121A MX378368B MX 378368 B MX378368 B MX 378368B MX 2018004121 A MX2018004121 A MX 2018004121A MX 2018004121 A MX2018004121 A MX 2018004121A MX 378368 B MX378368 B MX 378368B
- Authority
- MX
- Mexico
- Prior art keywords
- antigen receptors
- express
- antigen
- treatment
- diseases
- Prior art date
Links
- 102000006306 Antigen Receptors Human genes 0.000 title abstract 4
- 108010083359 Antigen Receptors Proteins 0.000 title abstract 4
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2015/073156 WO2017059900A1 (en) | 2015-10-07 | 2015-10-07 | Antigen receptors and uses thereof |
| PCT/EP2016/073792 WO2017060300A1 (en) | 2015-10-07 | 2016-10-05 | Antigen receptors and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018004121A MX2018004121A (es) | 2018-05-17 |
| MX378368B true MX378368B (es) | 2025-03-10 |
Family
ID=54288785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018004121A MX378368B (es) | 2015-10-07 | 2016-10-05 | Receptores de antigeno y usos de los mismos. |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20180282390A1 (enExample) |
| EP (2) | EP3617226A1 (enExample) |
| JP (1) | JP6657393B2 (enExample) |
| KR (1) | KR102084173B1 (enExample) |
| CN (2) | CN115536752A (enExample) |
| AU (1) | AU2016335217B2 (enExample) |
| BR (1) | BR112018006006A2 (enExample) |
| CA (1) | CA2998450C (enExample) |
| DK (1) | DK3359563T3 (enExample) |
| ES (1) | ES2748224T3 (enExample) |
| HU (1) | HUE046749T2 (enExample) |
| IL (1) | IL258079B (enExample) |
| MX (1) | MX378368B (enExample) |
| NZ (1) | NZ740474A (enExample) |
| PL (1) | PL3359563T3 (enExample) |
| PT (1) | PT3359563T (enExample) |
| SI (1) | SI3359563T1 (enExample) |
| WO (2) | WO2017059900A1 (enExample) |
| ZA (1) | ZA201801607B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018166589A1 (en) * | 2017-03-15 | 2018-09-20 | Biontech Cell & Gene Therapies Gmbh | Antigen receptors and uses thereof |
| PT3652215T (pt) | 2017-07-14 | 2021-05-18 | Immatics Biotechnologies Gmbh | Molécula de polipéptido com especificidade dupla melhorada |
| KR20250114570A (ko) * | 2017-09-22 | 2025-07-29 | 우시 바이올로직스 아일랜드 리미티드 | 신규한 이중특이적 폴리펩티드 복합체 |
| JP7185696B2 (ja) | 2017-09-22 | 2022-12-07 | ウーシー バイオロジクス アイルランド リミテッド | 新規な二重特異性ｃｄ３／ｃｄ１９ポリペプチド複合体相互参照 |
| CN107827959B (zh) * | 2017-11-09 | 2018-10-30 | 杭州续缓生物科技有限公司 | 识别乙肝病毒(hbv)表面抗原s183-91表位的tcr及其用途 |
| EP3904386A4 (en) * | 2018-12-28 | 2022-09-07 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Antibody and use thereof |
| US20220162312A1 (en) * | 2019-01-28 | 2022-05-26 | WuXi Biologics Ireland Limited | Novel bispecific cd3/cd20 polypeptide complexes |
| WO2021190580A1 (en) * | 2020-03-26 | 2021-09-30 | Wuxi Biologics (Shanghai) Co., Ltd. | Bispecific polypeptide complexes, compositions, and methods of preparation and use |
| BR112023022765A2 (pt) | 2021-05-05 | 2024-01-02 | Immatics Biotechnologies Gmbh | Proteínas de ligação ao antígeno que ligam especificamente o prame |
| WO2023215725A1 (en) * | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
| WO2024062138A1 (en) | 2022-09-23 | 2024-03-28 | Mnemo Therapeutics | Immune cells comprising a modified suv39h1 gene |
| EP4520334A1 (en) | 2023-09-07 | 2025-03-12 | Mnemo Therapeutics | Methods and compositions for improving immune response |
| WO2025052001A1 (en) | 2023-09-07 | 2025-03-13 | Mnemo Therapeutics | Methods and compositions for improving immune response |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| DE102006041455B4 (de) * | 2006-09-04 | 2011-07-28 | Johannes-Gutenberg-Universität Mainz, 55122 | Verfahren zur Herstellung einer einen stabilisierten funktionellen humanen Einzelketten-Antigen-erkennenden-TCR (scTCR) exprimierenden Zelllinie, damit hergestellt Zelllinie, stabilisierter TAA-spezifischer scTCR, deren Verwendungen und diese enthaltende pharmazeutische Zusammmensetzungen |
| AU2008253720B2 (en) * | 2007-05-11 | 2014-01-16 | Altor Bioscience Corporation | Fusion molecules and IL-15 variants |
| KR101612999B1 (ko) * | 2010-08-24 | 2016-04-15 | 로슈 글리카트 아게 | 활성화가능 이중특이적 항체 |
| WO2012131555A2 (en) * | 2011-03-25 | 2012-10-04 | Glenmark Pharmaceuticals S.A. | Hetero-dimeric immunoglobulins |
| TWI743461B (zh) * | 2011-03-28 | 2021-10-21 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| US9447194B2 (en) * | 2012-02-13 | 2016-09-20 | Seattle Children's Hospital | Bispecific chimeric antigen receptors and encoding polynucleotides thereof |
| DK2893004T3 (en) * | 2012-09-04 | 2019-02-04 | Cellectis | MULTI-CHAIN CHEMICAL ANTIGEN RECEPTOR AND APPLICATIONS THEREOF |
| WO2018166589A1 (en) * | 2017-03-15 | 2018-09-20 | Biontech Cell & Gene Therapies Gmbh | Antigen receptors and uses thereof |
-
2015
- 2015-10-07 WO PCT/EP2015/073156 patent/WO2017059900A1/en not_active Ceased
-
2016
- 2016-10-05 US US15/765,926 patent/US20180282390A1/en not_active Abandoned
- 2016-10-05 KR KR1020187010044A patent/KR102084173B1/ko active Active
- 2016-10-05 SI SI201630392T patent/SI3359563T1/sl unknown
- 2016-10-05 WO PCT/EP2016/073792 patent/WO2017060300A1/en not_active Ceased
- 2016-10-05 EP EP19187303.3A patent/EP3617226A1/en not_active Withdrawn
- 2016-10-05 ES ES16777681T patent/ES2748224T3/es active Active
- 2016-10-05 JP JP2018517521A patent/JP6657393B2/ja active Active
- 2016-10-05 AU AU2016335217A patent/AU2016335217B2/en active Active
- 2016-10-05 PT PT167776814T patent/PT3359563T/pt unknown
- 2016-10-05 CN CN202210717765.1A patent/CN115536752A/zh active Pending
- 2016-10-05 EP EP16777681.4A patent/EP3359563B8/en active Active
- 2016-10-05 DK DK16777681.4T patent/DK3359563T3/da active
- 2016-10-05 HU HUE16777681A patent/HUE046749T2/hu unknown
- 2016-10-05 NZ NZ740474A patent/NZ740474A/en unknown
- 2016-10-05 BR BR112018006006A patent/BR112018006006A2/pt active Search and Examination
- 2016-10-05 CN CN201680058729.1A patent/CN108137673B/zh active Active
- 2016-10-05 MX MX2018004121A patent/MX378368B/es unknown
- 2016-10-05 PL PL16777681T patent/PL3359563T3/pl unknown
- 2016-10-05 CA CA2998450A patent/CA2998450C/en active Active
-
2018
- 2018-03-08 ZA ZA2018/01607A patent/ZA201801607B/en unknown
- 2018-03-13 IL IL258079A patent/IL258079B/en unknown
-
2021
- 2021-09-18 US US17/478,906 patent/US20220033461A1/en not_active Abandoned
-
2022
- 2022-08-21 US US17/892,089 patent/US20230119334A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX378368B (es) | Receptores de antigeno y usos de los mismos. | |
| CO2017000506A2 (es) | Receptor quimérico de antígeno cll-1 | |
| CO2017001573A2 (es) | Receptor quimérico de antígeno anti-cd123 | |
| CO2017000507A2 (es) | Receptor quimérico de antígeno bcma | |
| CO2017000510A2 (es) | Constructos de car | |
| MX2018010733A (es) | Celulas que expresan multiples moleculas del receptor de antigeno quimerico (car) y usos de las mismas. | |
| MX2017005344A (es) | Composiciones y metodos para reforzar la eficacia de inmunoterapia celular adoptiva. | |
| NI201700019A (es) | Anticuerpos anti tigit | |
| CY1121217T1 (el) | Μεθοδοι για συγκομιδη καλλιεργειων κυτταρου θηλαστικων | |
| BR112016022841A2 (pt) | cadeia j modificada | |
| AR101845A1 (es) | Anticuerpos anti-her2 e inmunoconjugados | |
| MX2017010332A (es) | Predicción de epítopos de células t útiles para vacunación. | |
| MX362456B (es) | Anticuerpos y vacunas para utilizarse en el tratamiento de canceres por ror1 y para inhibir la metastasis. | |
| AR109625A1 (es) | Proteínas de unión a antígenos (abp) que se unen selectivamente a tigit y métodos para el uso de las mismas | |
| MX391279B (es) | Anticuerpos biespecíficos contra cd3 y cd20. | |
| MX2016013239A (es) | Tratamiento de cancer utilizando receptor quimerico de antigeno anti-cd19. | |
| ECSP17011657A (es) | Conjugados de fármacos con anticuerpos anti-cdh6 | |
| BR112017024123A2 (pt) | construtos de expressão e métodos de manipulação por engenharia genética de levedura metilotrófica | |
| MX2017016199A (es) | Formulacion de anticuerpo anti-cgrp. | |
| BR112014026740A8 (pt) | anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo | |
| MX2016016301A (es) | Procesos de siembra en serie y usos de los mismos. | |
| MX2017002469A (es) | Composiciones de matrices extracelulares. | |
| PE20151925A1 (es) | Anticuerpos anti-igf-1r con abolicion de la union al fcrn y su utilizacion en el tratamiento de enfermedades oculares vasculares | |
| BR112017009792A2 (pt) | anticorpos anti-pdgf-b e métodos de uso | |
| AR090668A1 (es) | Anticuerpo anti-adamts-5, derivados y usos del mismo |